UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 320

Sortiert nach

KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling

Nature communications, 2022-04, Vol.13 (1), p.2192-2192, Article 2192

2022

Volltextzugriff (PDF)

Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT

Breast cancer research and treatment, 2022-05, Vol.193 (1), p.65-81

2022

Volltextzugriff (PDF)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer

Cell death & disease, 2021-07, Vol.12 (7), p.684-684, Article 684

2021

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials

Cancers, 2023-05, Vol.15 (10), p.2858

2023

Volltextzugriff (PDF)

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Nature medicine, 2021-11, Vol.27 (11), p.1904-1909

2021

Volltextzugriff (PDF)

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

International journal of cancer, 2014-10, Vol.135 (8), p.1961-1969

2014

Volltextzugriff (PDF)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis

Journal of hematology and oncology, 2022-06, Vol.15 (1), p.72-72, Article 72

2022

Volltextzugriff (PDF)

Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study

Supportive care in cancer, 2020-08, Vol.28 (8), p.3819-3829

2020

Volltextzugriff (PDF)

UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb

Frontiers in oncology, 2023-02, Vol.13, p.992233-992233

2023

Volltextzugriff (PDF)

Emerging therapies for breast cancer

Journal of hematology and oncology, 2017-04, Vol.10 (1), p.98-17, Article 98

2017

Volltextzugriff (PDF)

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor

Breast cancer research : BCR, 2023-07, Vol.25 (1), p.81-81, Article 81

2023

Volltextzugriff (PDF)

Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study

Breast (Edinburgh), 2020-02, Vol.49, p.157-164

2020

Volltextzugriff (PDF)

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

Nature communications, 2022-07, Vol.13 (1), p.4025-4025, Article 4025

2022

Volltextzugriff (PDF)

Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest

Breast cancer research and treatment, 2022-02, Vol.192 (1), p.75-87

2022

Volltextzugriff (PDF)

Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China

BMC cancer, 2023-12, Vol.23 (1), p.1-1175, Article 1175

2023

Volltextzugriff (PDF)

Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer

Cancer medicine (Malden, MA), 2024-07, Vol.13 (14), p.e7472-n/a

2024

Volltextzugriff (PDF)

Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial

Investigational new drugs, 2022-04, Vol.40 (2), p.330-339

2022

Volltextzugriff (PDF)

CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database

Frontiers in oncology, 2022-11, Vol.12, p.1031706-1031706

2022

Volltextzugriff (PDF)

Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer

Frontiers in immunology, 2022-11, Vol.13, p.1056932-1056932

2022

Volltextzugriff (PDF)

Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients

Frontiers in oncology, 2022-05, Vol.12, p.894767-894767

2022

Volltextzugriff (PDF)

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211022881-17588359211022881

2021

Volltextzugriff (PDF)

Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211020528-17588359211020528

2021

Volltextzugriff (PDF)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

BMC cancer, 2011-06, Vol.11 (1), p.248-248, Article 248

2011

Volltextzugriff (PDF)

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer

Investigational new drugs, 2021-12, Vol.39 (6), p.1549-1558

2021

Volltextzugriff (PDF)

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

BMC medicine, 2023-08, Vol.21 (1), p.300-300, Article 300

2023

Volltextzugriff (PDF)

1 – 25 von 320

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(282)
Mit Volltextzugriff
(312)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling

Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer

Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis

Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study

UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb

Emerging therapies for breast cancer

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor

Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest

Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China

Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer

Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial

CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database

Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer

Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer

Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

Suchergebnisse filtern